QUARTERLY REVIEW中文

Madrigal Q3 2026: first profit and a sales beat, yet shares end 8% lower

By · AI-assisted, human-reviewed and edited · · Updated · 14 sources · Fact-checked · 7 min read

Did the story change? Better

Madrigal shares closed down 8.1% at $396.32 after trading up about 11% early, even though the results improved: Rezdiffra sales rose 18% from Q2 to $431.3 million, above the $404.2 million FactSet consensus, and Madrigal reported its first quarterly profit, $55.4 million. It narrowed the timing of its cirrhosis outcomes data to late 2027. It still gives no sales guidance and says it may dip in and out of profitability.

What it means

What changed
Madrigal reported its first quarterly profit, $55.4 million, and now expects cirrhosis outcomes data in late 2027, not just "2027".
What hasn't changed
Rezdiffra is still Madrigal's only product, and the company still gives no numeric sales guidance.
Next · Q1 2027
New Medicare Part D contracts take effect; the CFO expects 2027 discounts around the high end of the 2026 range.

Prices are official Nasdaq closes for Nov 2 and Nov 3, 2026.

Snapshot at the Nov 3, 2026 close

Market value
$9.2BIncluding convertible preferred and pre-funded warrants: $11.6B
Enterprise value
$8.6B
Price/sales
6.4×
P/E
n/m
Revenue growth
+93%
Net cash
$620M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $396.32 (official close, Nasdaq); 23.2 million shares (common shares on the cover page of the 10-Q filed Nov 3, 2026). n/m = not meaningful (e.g. negative earnings).

Madrigal shares reversed an early gain of about 11% and closed down 8.1% at $396.32, even though the results improved. It reported its first quarterly profit in Q3: $55.4 million, compared with a $114.2 million loss a year earlier. Sales of its only drug, the liver pill Rezdiffra, rose 50% to $431.3 million from $287.3 million. It also narrowed the expected timing of its main cirrhosis trial to late 2027 and announced a second one. It still gives no sales guidance, and it warned that profits may not hold every quarter.

The shares reversed an early gain

The results beat forecasts, but the shares still fell. Madrigal closed at $396.32, down 8.1% from $431.16, after trading about 11% higher in the first half hour (Nasdaq; Yahoo Finance). It was the stock’s lowest close since August 2025, 34% below its highest close of the past ten years, $602.83 in December 2025 (Nasdaq closing prices, our calculation). The S&P 500 rose 0.4% and the Nasdaq Composite 0.8%.

Madrigal’s release and call came before the fall and did not explain it, so the reason remains unconfirmed. Stocktwits attributed it to investors focusing on management’s comments that profit may not last in the near term. CFO Mardi Dier said Madrigal “may dip in and out of profitability”, and added that she expects “the growth of the top line” to “outstrip the spend”.

  • Net sales of $431.3 million were above the $404.2 million analysts polled by FactSet expected, according to MT Newswires (via Yahoo Finance). B. Riley (Buy rating) had forecast sales near $415 million before the results, based on its analysis of IQVIA data, Investing.com reported.
  • Diluted earnings were $1.83 a share, against a FactSet consensus loss of $0.86, according to MT Newswires.
  • More than 55,850 patients were on Rezdiffra at Sep 30, up from more than 49,000 at Jun 30 and nearly twice the more than 29,500 reported a year earlier.
  • Citi (Buy rating) raised its price target to $760 from $725 (MarketBeat) after what it called “another strong quarter” (Stocktwits).

Did the story change?

In July management expected cirrhosis outcomes data in 2027; now it specifies late 2027. The table compares Q2 with Q3 and shows which management expectations changed.

Driver Q2 → Q3 2026 Management: before → now Signal
Net sales $364.3M → $431.3M (+18% on Q2; +50% year on year) No numeric guidance (Jul 30) → still none; the CFO feels good about “the consensus growth rate” from Q3 to Q4 (Nov 3) Better
Patients on Rezdiffra More than 49,000 → more than 55,850 “Steadily add patients” (CEO, Jul 30) → the same phrase (CEO, Nov 3) Better
Profit Operating loss −$56.3M → operating income +$56.0M; net income $55.4M “We do not expect to be profitable in 2026” (CFO, Jun 10; the CEO clarified this meant the full year) → first profitable quarter, but Madrigal “may dip in and out of profitability” (CFO, Nov 3) Better
Discounts and rebates (gross-to-net proxy; our calculation)1 About 32% → about 32.5% Mid-to-high-30% for 2026 → the low end of that range for 2026; about the high end in 2027 (CFO, Nov 3) Watch
Cirrhosis outcomes data (MAESTRO-NASH OUTCOMES) Event-driven trial under way “Tracking to 2027” (Jul 30) → “late 2027” (Nov 3) Watch

Sources: the company’s Q2 and Q3 releases and 10-Qs; Nov 3 call remarks from MarketBeat’s transcript; Jul 30 call remarks from Stock Analysis’s Q2 call transcript; Jun 10 remarks from Stock Analysis’s conference transcript. The percentage changes are our calculations from reported figures.

What got better

Sales, patients and cash

Net sales rose 18% from Q2, faster than the 17% rise from Q1 to Q2 (our calculation). Chief executive Bill Sibold said doctors are “prescribing it more often” and that sales are now “annualizing at more than $1.7 billion”. Madrigal estimates that more than 530,000 US patients with moderate-to-advanced liver scarring from MASH had been diagnosed by Jun 30. It expects that number to grow more than 30% in 2026.

Cash generation strengthened from Q2. Operating cash flow was about +$120.6 million in Q3, and free cash flow (operating cash flow less capital spending) was about +$116.6 million, against +$19.1 million in Q2 (our calculation)2. Cash, cash equivalents and marketable securities rose to $961.0 million from $838.8 million at Jun 30.

Profit

Operating income was $56.0 million, against a $56.3 million operating loss in Q2. Research and development spending fell to $71.8 million from $91.2 million in Q2. A year earlier, Q3 included $117.3 million of one-time licensing expenses. Excluding them, prior-year R&D was $56.7 million, so this quarter’s R&D was about 27% higher (our calculation).3 Selling, general and administrative costs fell to $265.7 million from $289.4 million in Q2. The CFO said SG&A will be higher in Q4 than in Q3 because of the timing of marketing spending.

What needs watching

Profits may not hold every quarter

The trade-off: Madrigal is choosing to keep spending on its sales push and pipeline rather than protect quarterly profits. CFO Mardi Dier said the company remains “a top-line growth story” and “may dip in and out of profitability” because of investment timing, licensing deals and “typical 1Q dynamics” for specialty drugs. For the first nine months of 2026, Madrigal still lost $96.9 million.

Discounts in 2027

Madrigal is negotiating Medicare Part D contracts that take effect in the first quarter of 2027. The CFO said the big step-up in discounts came between 2025 and 2026, and that 2027 gross-to-net should be “plus or minus the high end” of this year’s mid-to-high-30% range. By our calculation, Q3 discounts were about 32.5% of gross sales1, below that range.

Competition and the cirrhosis race

Novo Nordisk’s Wegovy has been approved for MASH with moderate-to-advanced scarring since August 2025 (FDA). On the call, Goldman Sachs analyst Andrea Newkirk (Buy rating) asked how growing GLP-1 use affects Madrigal’s outcomes trial. Chief medical officer Dave Soergel said about 25–30% of trial patients were on a stable GLP-1 at the start and that adding one later would be a protocol deviation.

In compensated cirrhosis (F4c), GSK lists efimosfermin alfa in Phase 3. Sibold said competitors have “delayed their timelines, with the earliest potential entrant now not expected until 2030.” To extend its lead, Madrigal plans MAESTRO-CSPH, a second Phase 3 outcomes trial with more than 2,000 patients enriched for portal hypertension. It expects to start the trial in the first half of 2027, subject to FDA talks, with results in the early 2030s.

An analyst from Ash Verma’s team at UBS (Buy rating) questioned the main trial’s assumptions, saying controlled cirrhosis studies had reported placebo event rates of about 2–3% and asking why Madrigal expected more than 5%. Soergel said Madrigal assumes 5–10% because it enriched the trial for patients at higher risk.

Does this change the long-term story?

Our read: it strengthens the near-term case, with growing sales, a first profit and cash coming in, without settling the bigger questions. Rezdiffra is still Madrigal’s only product, and its US approval still depends on outcomes data. Discounts are set to rise with Medicare contracts in 2027. The cirrhosis readout, now expected in late 2027, is the event that would decide whether Rezdiffra’s market roughly doubles, as Sibold said it could.

For the full record of filings, dilution and cash, see Madrigal Pharmaceuticals: The Long View.

Footnotes

  1. Our gross-to-net proxy divides the quarterly change in the provision related to current-year sales by net product revenue plus that change, from the reserve rollforward in the 10-Qs. It is not necessarily the same as management’s measure. Q3 2026: provision $549.431M (nine months) − $341.687M (six months) = $207.744M; $207.744M ÷ ($431.268M + $207.744M) = 32.5%. Q2 2026: about 32%, as calculated in the Long View. ↩ ↩2

  2. Q3 = nine months − six months. Operating cash flow: −$23.550M − (−$144.106M) = +$120.556M. Capital spending: −$12.030M − (−$8.102M) = −$3.928M. Free cash flow = +$116.628M. Q2 free cash flow +$19.1M is from the Long View’s calculation. ↩

  3. Prior-year R&D excluding the licensing expense = $174.004M − $117.300M = $56.704M. Growth = $71.755M ÷ $56.704M − 1 = 26.5%. ↩

What to watch next

Nov 5–9, 2026
Madrigal presents 18 abstracts at the AASLD Liver Meeting, including 13 based on real-world use of Rezdiffra.
Q1 2027
New Medicare Part D contracts take effect. The CFO expects 2027 gross-to-net discounts "plus or minus the high end" of the 2026 range of mid-to-high 30%.
First half of 2027
Planned start of MAESTRO-CSPH, a second Phase 3 outcomes trial in compensated cirrhosis with more than 2,000 patients, subject to talks with the FDA.
2027
Planned starts of three Phase 2 trials combining Rezdiffra with ervogastat, MGL-2086 and MGL-0795, following regulatory discussions.
Late 2027
MAESTRO-NASH OUTCOMES results in compensated cirrhosis. Madrigal says a positive result would support a cirrhosis indication and full approval.

Quick questions

Is Madrigal now profitable?

It reported its first quarterly profit in Q3 2026: net income of $55.4 million, against a loss of $57.9 million in Q2. It is still loss-making for the first nine months of 2026, and its CFO said it "may dip in and out of profitability" in the near term.

When are Madrigal's cirrhosis outcomes data due?

Madrigal now expects MAESTRO-NASH OUTCOMES results in late 2027; earlier it gave only "2027". The trial is event-driven, so timing depends on how fast clinical events accumulate.

Does Madrigal give sales guidance?

No. On the Q3 call the CFO said Madrigal is "not providing guidance", though she said the company feels good about the consensus growth rate from Q3 to Q4.

Updates

  • : Updated Nov 3, after the close: this review first went out with a morning price, when the shares were about 11% higher. They closed down 8.1% at $396.32, so we rewrote the headline, the summary and the section on the share move, and updated the valuation snapshot to the Nov 3 close. The company results and figures are unchanged.

About Madrigal: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.